SXI Life Sciences
6.905,90
PKT
+48,39
PKT
+0,71
%
Werbung
Analysen zu SXI Life Sciences-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 19.01.05 | Novartis Equal-weight | Morgan Stanley | |
| 19.01.05 | BB Biotech Kaufen | Hamburger Sparkasse | |
| 19.01.05 | Tecan (N) Reduce | Helvea | |
| 19.01.05 | Straumann Accumulate | Helvea | |
| 21.01.05 | Novartis Kaufen | Helaba Trust | |
| 18.01.05 | Novartis Buy | AG Edwards | |
| 18.01.05 | Novartis Buy | Merrill Lynch | |
| 18.01.05 | Novartis Outperform | Bear Stearns | |
| 18.01.05 | Lonza Buy | Helvea | |
| 18.01.05 | Roche Buy | Merrill Lynch | |
| 18.01.05 | Siegfried Neutral | Helvea | |
| 18.01.05 | Novartis Buy | Merrill Lynch | |
| 18.01.05 | Novartis Akkumulieren | Independent Research | |
| 18.01.05 | Novartis Buy | Sarasin Research | |
| 17.01.05 | Lonza Reduce | Sarasin Research | |
| 17.01.05 | Novartis Sector Outperform | Vontobel | |
| 14.01.05 | Novartis Kaufen | Helaba Trust | |
| 18.01.05 | Novartis Empfehlungsliste | Erste Bank | |
| 14.01.05 | Novartis Overweight | Lehman Brothers | |
| 18.01.05 | Straumann Outperform | Credit Suisse First Boston | |
| 17.01.05 | Tecan (N) Neutral | Credit Suisse First Boston | |
| 17.01.05 | Basilea Pharmaceutica Outperform | Credit Suisse First Boston | |
| 17.01.05 | Sonova Outperform | Credit Suisse First Boston | |
| 13.01.05 | Novartis Buy | AG Edwards | |
| 12.01.05 | Novartis Hold | Smith Barney Citigroup | |
| 13.01.05 | Novartis Kaufen | Hamburger Sparkasse | |
| 11.01.05 | Novartis Sell | Banc of America Sec. | |
| 10.01.05 | Lonza Underperform | Goldman Sachs | |
| 11.01.05 | Novartis Empfehlungsliste | Erste Bank | |
| 04.01.05 | Novartis Buy | Deutsche Securities | |
| 18.01.05 | Novartis Outperform | Goldman Sachs |